5 Key Takeaways

• 1

  Age-related macular degeneration (AMD) is a leading cause of vision impairment in individuals aged 50 and older.

• 2

  Current anti-VEGF therapies have transformed wet AMD management but do not address all VEGF isoforms and have a high treatment burden.

• 3

  Small-molecule tyrosine kinase inhibitors (TKIs) are under clinical evaluation for wet AMD, targeting VEGF receptors and other relevant pathways.

• 4

  Sustained-release formulations of TKIs, like axitinib and vorolanib, aim to reduce treatment burden and improve long-term vision outcomes.

• 5

  Emerging therapies, including TKIs, may reshape AMD management by offering broader pathway inhibition and minimizing fluid fluctuations.